Beyond Botanicals has helped launch over 400 health and wellness brands in the last decade. If you’re looking for a Private Label CBD Supplier in the USA with low minimums and fast turnaround, we can help you find the perfect partner and take over account management on your behalf. We offer custom blending and formulation for a wide range of FDA-audited supplement products. Our manufacturers are FDA-registered and cGMP compliant. We are proud to work with the leading private label CBD manufacturers in the United States and look forward to helping grow your brand. Private Label CBD is where customized premium CBD products are made just for you. We start with lab-tested, high-quality base oils from 100% American hemp and create custom hemp cosmetics, tinctures and oil blends that meet your specifications. Customizations include terpenes, flavors or fragrances, CBD dosages, custom containers and Balance Bloom CBD official packaging. Our consultants and designers can even assist you with branding your new CBD company.

Private Label CBD allows you to launch your own products with a team that understands the ever-changing regulatory framework of the CBD industry and stays ahead of the curve, helping make sure your launch and presence in the market is done right. This includes lab testing and custom-branded Certificates of Analysis for your Balance Bloom CBD official products. Our Private Label CBD program has low minimums and fast turnaround to help you start your own CBD company quickly and within budget. Launching a product line is a long journey with many components. You also need to consider how to sell your product, how to accept payments, and how to maintain regulatory compliance in a rapidly changing industry. Timely shipping and great customer service are critical in keeping up with major industry players. Our consultants are experts in these spaces! We can teach you how to perform the tasks on your own, train your team, or outsource them entirely. Beyond Botanicals offers affordable subscription-based services for website management, payment processing, fulfillment, customer service, and audit preparation.

After clearing its way through EU-GMP certification, a North Macedonian company is now able to export medical cannabis products to the EU. How will this affect the landscape of medical cannabis in Europe? In Macedonia, cannabis is not legal for recreational use at all, and there are no decriminalization or personal use laws to boot. However, in 2016, Macedonia did approve a bill for medical cannabis within the country. As per Macedonian laws, which sync with EU laws here, oils and extracts can have up to .2% THC and still be sold without a prescription. Cannabis with any higher THC amount can be obtained through prescription. The laws allow for private citizens to make use of medical cannabis, as well as for Macedonia to enter into the legal medical cannabis market with laws to cover cultivation, production, and exportation for medicinal use. Since that time, and according to internal legislation, Macedonia has been exporting extracts, oils, and tinctures, but that’s it.

And while that does account for about 30% of the market, the great majority - 70% - relies on smokable hemp flowers, which Macedonia had not been cleared to export at all. Until now though, the EU was not included in exportable locations for any goods as no companies had EU-GMP authorization. What’s the biggest problem? One of the biggest issues for Macedonia is that cannabis flowers have not been legalized for exportation. A big factor in this inability comes from internal licensing issues that stem from allegations of corruption. The allegations centered around former Prime Minister Zoran Zaev showing preferential treatment when giving out licenses, opting to give them to friends and family members which would, in turn, benefit him personally. There were also a lot of questions and calls for specifications relating to how licensing would generally work, issues related to the program being government run, and opposition to the €500 bank guarantee that many thought would make it harder for smaller enterprises to gain ground.